'김갑성' 기자의 전체기사
-
WuXi AppTec Awarded Gold Medal by EcoVadis Sustainability…
SHANGHAI, Sept. 8, 2025 -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has received the Gold Medal by EcoVadis sustainability rating for the second consecutive year. This achievement reflects WuXi AppTec's commitment to sustainability and its ongoing efforts to integrate environmental and social responsibilities into the Company's business strategies and operations. EcoVadis is a leading sustainability rating agency for global supply chains.
- 김갑성 기자
- 2025-09-08 20:00
-
BrainCo Helps Amputee Showcase Technology at WAIC 2025
BOSTON, Sept. 8, 2025 -- At the 2025 World Artificial Intelligence Conference (WAIC) in August 2025, Gu demonstrated the BrainCo Intelligent Bionic Hand. He played the piano with precision and even explained to attendees how brain-computer interface (BCI) technology enables amputees to control prosthetic devices with their own neural signals. His presentation drew enthusiastic applause, offering the audience a vivid glimpse of how advanced technology is reshaping human potential. BrainCo, a global leader in non-invasive brain-computer interface (BCI) technology, continues to transform
- 김갑성 기자
- 2025-09-08 19:29
-
FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®…
This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 -- Echosens, the leader in non-invasive liver diagnostics, is announcing today that the U.S. Food and Drug Administration's (FDA's) Center for Drug Evaluation and Research (CDER), Office of New Drugs has accepted the company's Letter of Intent for the qualification of Liver Stiffness Measurement by Vibration-Controlled Transient Elastography (FibroScan®) as a reasonably likely su
- 김갑성 기자
- 2025-09-08 18:00
-
Remplir™ Study Delivers Compelling 81% Success Rate
Data to support US sales roll out and EU + UK regulatory submissions Interim results from a new Remplir™ study demonstrated a compelling overall treatment success rate of 81.1% following nerve repair procedures. Real World Evidence (RWE) patient data collected in the study confirms Orthocell's nerve repair product, Remplir, as the ideal medical device for connecting severed nerves, protecting damaged nerves, or capping nerve ends after amputation. The data demonstrated: 83.9% of muscles innervated by repaired nerves achieved functional motor recovery. 89.5% of nerv
- 김갑성 기자
- 2025-09-08 17:32
-
Servier acquires potential treatment for Fragile X syndrome, th…
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA Acquisition strengthens Servier's neurology pipeline in line with its 2030 strategy SURESNES, France, Sept. 8, 2025 -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into a definitive agreement with Kaerus Bioscience for the acquisition
- 김갑성 기자
- 2025-09-08 15:49
-
Gushengtang's H1 2025 Net Profit Climbs 41.6% Driven by Digital He…
GUANGZHOU, China, Sept. 8, 2025 -- On August 29, Gushengtang (HKG:2273) announced its interim results for 2025, reporting strong operational and financial performance. The company posted revenue of RMB 1.49 billion, representing a 9.5% year-on-year increase. Net profit grew 41.6% year-on-year to RMB 150 million. The expansion in net profit significantly outpaced top-line growth, reflecting improved profitability and greater operating leverage. The company also delivered robust cash flow. Operating cash flow reached RMB 300 million, up 111% from the prior year, while free cash flow tota
- 김갑성 기자
- 2025-09-08 15:35
-
Siriraj × MIT Hacking Medicine 2025 Now Open for Applications A…
BANGKOK, Sept. 8, 2025 -- Siriraj Hospital and MIT Hacking Medicine have joined forces once again to host the second edition of their medical innovation hackathon, Siriraj × MIT Hacking Medicine 2025, taking place from October 31 to November 2, 2025. Applications are now open for participants across Southeast Asia. The event aims to bring together multidisciplinary professionals to develop innovative solutions in medical treatment and healthcare services, all within an ecosystem of hospitals, faculties of engineering and accountancy, the private sector, investors, and incubation program
- 김갑성 기자
- 2025-09-08 14:39
-
Merz Aesthetics® Tops Best Workplaces in Asia™ 2025 List b…
SINGAPORE, Sept. 8, 2025 -- Merz Aesthetics, the world's largest dedicated medical aesthetics business has officially been recognized as No.1 under Best Workplace in Asia 2025 in the Small & Medium Business category by Great Place To Work, celebrating its commitment to a truly inclusive, people-first culture. With a proud 117-year heritage as a family-owned business, Merz Aesthetics has always taken the long view of success - investing in people, advancing innovation, and nurturing a culture of respect, integrity, and trust. This recognition underscores the company'
- 김갑성 기자
- 2025-09-08 12:50
-
Sirnaomics Announces Strategic Equity Investment by Bloom…
HONG KONG, Sept. 7, 2025 -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; Stock Code: 2257), a leading biopharmaceutical company in discovery and development of advanced RNAi therapeutics, today announced that it has entered into a strategic investment agreement with Bloomage Biotech (stock code: 688363.SH) through its wholly-owned subsidiary, Bloomage Biotechnology (Hong Kong) Limited. Under the terms of the agreement, Bloomage Biotech has subscribed for shares in Sirnaomics' strategic placement at HKD 12 per
- 김갑성 기자
- 2025-09-08 12:15
-
DRONTECH ASIA 2025 RETURNS TO KUALA LUMPUR, SHOWCASING CUTTIN…
[ 메디채널 김갑성 기자 ] The region's premier drone and UAV exhibition and conference enters its second edition with strong global participation, a high-level opening by Malaysia's Deputy Minister of Investment, Trade and Industry, and a mission to drive ASEAN's leadership in unmanned technologies. KUALA LUMPUR, Malaysia, Sept. 8, 2025 -- Aerosea Exhibitions Sdn Bhd is proud to announce the return of DronTech Asia 2025, the region's premier drone and UAV exhibition and conference, taking place from 30 September to 2 October 2025 at MITEC, Kuala Lumpur, under the theme "Pushing the Bounda
- 김갑성 기자
- 2025-09-08 10:40
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-22_WED
2025-10-21_TUE
- AESOP Technology announces DxPrime is now a qualified solution on Mayo Clinic Platform 23:30
- Charming Medical Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq 23:00
- Stéphane Rolland's Haute Couture to Illuminate the 10th Anniversary of Barcelona Bridal Night 23:00
- JOY GROUP Completes Acquisition of Italian Dermatological Hair Care Brand Foltène 22:00
- AI meets capital: Bizcap welcomes 8fig into its global portfolio to accelerate growth funding 22:00
- Youth Innovation Safeguards Green Heritage: 2025 World Food Forum Youth Action on Green Agri-Heritage Held in Rome 21:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 22일 03시 00분